Esoteric Testing Market

Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) (2022 - 2026)

Report Code: MD 5930 Jun, 2021, by marketsandmarkets.com

[244 Pages Report] The global esoteric testing market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period. The market growth is fueled by the high prevalent infectious and chronic diseases, advancing precision medicines, and early diagnosis.

The Asian countries offer vast opportunities of growth in the market. However, the hindrance caused by the inadequate reimbursements may restrict the market growth to a certain limit. The esoteric testing market is segmented based on type, technology, end user and region.

Esoteric Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the esoteric testing market

The market growth has seen a decline in its pace, due to the sudden outbreak of the COVID-19. In the first quarter of 2020, companies faced certain operational and logistic challenges due to the imposition of lockdowns. Eventually, with the massive influx of COVID-19 patients and tremendous demand for mass scale diagnosis in various regions, companies escalated and deviated their focus from esoteric tests to the diagnostic offerings for COVID-19.

Global Esoteric Testing Market Dynamics

DRIVER: Growing geriatric population, increasing prevalence of chronic and infectious diseases, advancing esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer and precision medicine.

The chronic diseases such as diabetes, cardiovascular diseases and cancer are on rise across the globe. The prevalence of infectious disease such as Dengue, Hepatitis B, C, HIV, Malaria, Tuberculosis, and others, are also increasing at an alarming rate. The awareness of the esoteric tests is increasing for the early and effective diagnosis of such diseases. The advancing technology of esoteric test are offering expedited results with higher efficacy, detection limits, and sensitivity. The increasing use of esoteric DNA sequencing, NGS technologies and whole genome sequencing in the early diagnosis of cancer, precision and personal medicine are also pushing the growth of the market.

RESTRAINT: Inadequate reimbursement of the esoteric tests

Inadequate reimbursement is a major factor restraining the growth of the esoteric testing market. The coverage of precision medicine and personalized medicine by Medicare are highly confined. In the past few years, there has been a decline in the reimbursement of diagnostic tests, which has negatively impacted the volume of tests. This resulted due to the increased controls over the utilization of laboratory services by Medicare, Medicaid, and other third-party payers, particularly managed care organizations (MCOs).

OPPORTUNITY: Emerging technologies in esoteric testing and emerging economies

Emerging technologies such as biomarker analysis, digital PCR, NGS, pyrosequencing, or Sanger sequencing, digital microfluidic platforms and advanced molecular phenotyping technologies are expected to thrust the growth of the market. The emerging economies such as India, China, and India are expected to offer potential growth opportunities for major players operating in the esoteric testing market. This can be attributed to the growing geriatric population, high prevalence of chronic and infectious diseases, improving healthcare infrastructure, and increasing disposable income in these countries.

CHALLENGES: Dearth of Skilled Professionals

The dearth of a skilled workforce has been a challenge for several decades, resulting in an aging workforce and declining enrolment in training programs. It takes almost five to ten years of continuous practice in clinical laboratory work for technicians to gain expertise. Esoteric tests are more advanced clinical laboratory tests than routine molecular tests.

Infectious disease testing segment dominated the esoteric testing market in 2020.

Based on type, the market is segmented into infectious disease testing, neurology testing, toxicology testing, endocrinology testing, genetic testing, immunology testing, oncology testing, and other testing. The infectious disease testing segment accounted the largest share in the market owing to the high demand technical advancement of the molecular testing. The improving healthcare infrastructure of the developing countries have also supported the large share of the segment. The genetic testing segment is expected to grow with the fastest CAGR due to the advancing NGS sequencing technology.

CLIA held the largest share of the esoteric testing market during the forecast period.

Based on technology, market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), flow cytometry, real-time PCR, DNA sequencing, mass spectrometry, and other technologies. CLIA accounted for the largest share in the market owing to its high performance and efficacy of diagnosis.

Esoteric Testing Market  by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for esoteric testing market in 2020.

The esoteric testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America held the largest share in the global market, followed by Europe. The dominance of North America is driven by the massive per capita healthcare expenditure, vast population base of geriatric and chronic disease patients and the presence of leading companies in the region.

Key Market Players

The prominent players operating in this market include Labcorp (US), Quest Diagnostics (US), and OPKO Health Inc. (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2018–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

Type, Technology, End User and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

Labcorp (US), Quest Diagnostics (US), and OPKO Health (US). The other players operating into this market include, H.U. Group Holdings, Inc. (Japan), Healius Limited (Australia), Sonic Healthcare (Australia), Mayo Foundation for Medical Education and Research (MFMER, US), Eurofins Scientific (Luxembourg), Stanford Clinical Pathology (US), Foundation Medicine (US), Kindstar Global (Beijing) Technology, Inc. (China), ARUP Laboratories (US), Georgia Esoteric & Molecular Laboratory, LLC (US), Thyrocare Technologies Ltd. (India), ACM Global Laboratories(US), BioAgilytix Labs (US), National Medical Services Inc. (NMS) (US), Baylor Esoteric and Molecular Laboratory (US), Cerba Xpert (Belgium), HealthQuest Esoterics (US), BUHLMANN Diagnostics Corp (BDC, US), BP Diagnostic Centre SDN BHD (Malaysia), Flow Health (US), and Leo Labs, Inc. (India).

This report categorizes the esoteric testing market into the following segments and subsegments:

By Type

  • Infectious Diseases Testing
  • Endocrinology Testing
  • Oncology Testing
  • Genetics Testing
  • Toxicology Testing
  • Immunology Testing
  • Neurology Testing
  • Other Testing

By Technology

  • Chemiluminescence Immunoassay
  • Enzyme-Linked Immunosorbent Assay
  • Mass Spectrometry
  • Real-Time PCR
  • DNA Sequencing
  • Flow Cytometry
  • Other Technologies

By End User

  • Independent & Reference Laboratories
  • Hospital-Based Laboratories

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • UK
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of the Latin America
  • Middle East & Africa

Recent Developments

  • In May 2021, Labcorp will acquire Myriad Genetics’ autoimmune business unit.
  • In February 2021, Quest Diagnostics collaborated with GRAIL to support a first-of-its-kind multi-cancer early detection blood test called Galleri.
  • In January 2021, OPKO Health Inc. (BioReference Laboratories) launched Scarlet Health, an in-home diagnostic, fully integrated digital platform, in the US.
  • In March 2019, H.U. Group Holdings’ subsidiary, Miraca Holdings, partnered with the Chugai Pharmaceutical Co., Ltd.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 27)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SEGMENTATION
           1.3.1 MARKETS COVERED
                    FIGURE 1 ESOTERIC TESTING MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA
           FIGURE 2 ESOTERIC TESTING MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF ESOTERIC TESTING SERVICES
           FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 7 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           2.3.1 SECONDARY DATA
           2.3.2 PRIMARY DATA
                    FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
           2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
    2.6 LIMITATIONS
    2.7 RISK ASSESSMENT
           TABLE 2 RISK ASSESSMENT
    2.8 COVID-19 ECONOMIC ASSESSMENT
    2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 11 ESOTERIC TESTING MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
    FIGURE 12 GLOBAL MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
    FIGURE 13 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
    FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 GLOBAL OVERVIEW
           FIGURE 15 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY AND COUNTRY (2020)
           FIGURE 16 ELISA SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020
    4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 17 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE GLOBAL MARKET FROM 2021 TO 2026
    4.4GLOBAL MARKET: REGIONAL MIX (2021–2026)
           FIGURE 18 APAC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
    4.5 GLOBAL MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 55)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 20 ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing geriatric population and the increasing prevalence of chronic and infectious diseases
                               FIGURE 21 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                               FIGURE 22 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
                               TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
                               FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
                               TABLE 4 ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES
                    5.2.1.2 Increasing use of esoteric DNA sequencing technologies in precision medicine and the early diagnosis of cancer
                    5.2.1.3 Advancements in esoteric tests for personalized medicine
                    5.2.1.4 Increasing research funding for precision medicine, genetic analysis, and personalized medicine
                    5.2.1.5 Growing number of collaborations in the esoteric testing market
           5.2.2 RESTRAINTS
                    5.2.2.1 Inadequate reimbursement
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging technologies in esoteric testing
                    5.2.3.2 Growth opportunities in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Dearth of skilled professionals
    5.3 COVID-19 IMPACT ANALYSIS
           5.3.1 COVID-19 HEALTH ASSESSMENT
                    FIGURE 24 COVID-19 GLOBAL PROPAGATION
    5.4 IMPACT OF COVID-19 ON THE ESOTERIC TESTING MARKET
           FIGURE 25 KEY PLAYERS: REVENUE IMPACT
    5.5 REGULATORY OVERVIEW
           TABLE 5 STRINGENCY OF REGULATIONS FOR CLINICAL LABORATORY ACCREDITATION, BY COUNTRY
           5.5.1 NORTH AMERICA
                    5.5.1.1 US
                    5.5.1.2 Canada
           5.5.2 EUROPE
                    TABLE 6 ACCREDITATION BODIES IN EUROPE
           5.5.3 ASIA PACIFIC
                    5.5.3.1 Japan
                    5.5.3.2 India
                    5.5.3.3 China
    5.6 TECHNOLOGY ANALYSIS
           TABLE 7 KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES
    5.7 AVERAGE SELLING PRICE TREND
           TABLE 8 AVERAGE SELLING PRICE OF ESOTERIC TESTS, 2021
    5.8 PATENT ANALYSIS
           FIGURE 26 LIST OF MAJOR PATENTS FOR THE ESOTERIC TESTING
           FIGURE 27 REGIONAL ANALYSIS OF PATENTS GRANTED FOR THE ESOTERIC TESTING MARKET, 2015-2020
           TABLE 9 INDICATIVE LIST OF ESOTERIC TESTING PATENTS
    5.9 VALUE CHAIN ANALYSIS
           FIGURE 28 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
    5.10 SUPPLY CHAIN ANALYSIS
           FIGURE 29 DIRECT DISTRIBUTION IS THE PREFERRED STRATEGY FOR PROMINENT LABORATORIES
    5.11 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
                    FIGURE 30 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
           5.11.1 ROLE IN THE ECOSYSTEM
                    TABLE 10 GLOBAL MARKET: ECOSYSTEM
                    FIGURE 31 KEY PLAYERS IN THE GLOBAL MARKET ECOSYSTEM
    5.12 DISRUPTIVE TECHNOLOGIES IN THE MARKET
                    FIGURE 32 DISRUPTIVE TECHNOLOGIES IN THE GLOBAL MARKET
    5.13 PORTER’S FIVE FORCES ANALYSIS
                    TABLE 11 HIGH FRAGMENTATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS
           5.13.1 INTENSITY OF COMPETITIVE RIVALRY
           5.13.2 BARGAINING POWER OF SUPPLIERS
           5.13.3 BARGAINING POWER OF BUYERS
           5.13.4 THREAT OF SUBSTITUTES
           5.13.5 THREAT OF NEW ENTRANTS

6 ESOTERIC TESTING MARKET, BY TYPE (Page No. - 82)
    6.1 INTRODUCTION
           TABLE 12 ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
    6.2 INFECTIOUS DISEASE TESTING
           6.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
                    TABLE 13 EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES
                    TABLE 14 ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    6.3 ENDOCRINOLOGY TESTING
           6.3.1 INCREASING INCIDENCE OF DIABETES TO DRIVE THE ADOPTION OF ESOTERIC TESTS
                    TABLE 15 ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    6.4 ONCOLOGY TESTING
           6.4.1 RISING PREVALENCE OF CANCER TO DRIVE THE MARKET FOR ESOTERIC TESTING
                    TABLE 16 GLOBAL INCIDENCE OF CANCER IN MEN, 2020
                    TABLE 17 GLOBAL INCIDENCE OF CANCER IN WOMEN, 2020
                    TABLE 18 EXAMPLES OF ESOTERIC TESTS FOR THE DIAGNOSIS OF CANCER
                    TABLE 19 ESOTERIC ONCOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    6.5 GENETIC TESTING
           6.5.1 ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH
                    TABLE 20 ESOTERIC GENETIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    6.6 TOXICOLOGY TESTING
           6.6.1 INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION HAVE INCREASED THE DEMAND FOR ESOTERIC TESTING
                    TABLE 21 ESOTERIC TOXICOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    6.7 IMMUNOLOGY TESTING
           6.7.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
                    TABLE 22 INCIDENCE OF AUTOIMMUNE DISEASES, BY TYPE
                    TABLE 23 EXAMPLES OF ESOTERIC TESTS AVAILABLE FOR IMMUNOLOGY TESTING
                    TABLE 24 ESOTERIC IMMUNOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    6.8 NEUROLOGY TESTING
           6.8.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDER TO DRIVE MARKET GROWTH
                    TABLE 25 EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS
                    TABLE 26 ESOTERIC NEUROLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    6.9 OTHER TESTING
           TABLE 27 OTHER GLOBAL MARKET, BY REGION, 2018–2026 (USD MILLION)

7 ESOTERIC TESTING MARKET, BY TECHNOLOGY (Page No. - 96)
    7.1 INTRODUCTION
           TABLE 28 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
    7.2 CHEMILUMINESCENCE IMMUNOASSAY
           7.2.1 RISING GERIATRIC POPULATION TO AID MARKET GROWTH
                    TABLE 29 GLOBAL MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018–2026 (USD MILLION)
    7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
           7.3.1 GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO DRIVE MARKET GROWTH
                    TABLE 30 EXAMPLES OF ESOTERIC ELISA TESTS
                    TABLE 31 GLOBAL MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018–2026 (USD MILLION)
    7.4 MASS SPECTROMETRY
           7.4.1 MASS SPECTROMETRY IS USED IN ENDOCRINE TESTING AND INFECTIOUS DISEASE DIAGNOSIS
                    TABLE 32 EXAMPLES OF ESOTERIC MASS SPECTROMETRY TESTS
                    TABLE 33 ESOTERIC TESTING MARKET FOR MASS SPECTROMETRY, BY REGION, 2018–2026 (USD MILLION)
    7.5 REAL-TIME PCR
           7.5.1 INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO DRIVE MARKET GROWTH
                    TABLE 34 GLOBAL MARKET FOR REAL-TIME PCR, BY REGION, 2018–2026 (USD MILLION)
    7.6 DNA SEQUENCING
           7.6.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH
                    TABLE 35 EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING
                    TABLE 36 GLOBAL MARKET FOR DNA SEQUENCING, BY REGION, 2018–2026 (USD MILLION)
    7.7 FLOW CYTOMETRY
           7.7.1 RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET GROWTH
                    TABLE 37 GLOBAL MARKET FOR FLOW CYTOMETRY, BY REGION, 2018–2026 (USD MILLION)
    7.8 OTHER TECHNOLOGIES
           TABLE 38 GLOBAL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2026 (USD MILLION)

8 ESOTERIC TESTING MARKET, BY END USER (Page No. - 106)
    8.1 INTRODUCTION
           TABLE 39 ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
    8.2 INDEPENDENT & REFERENCE LABORATORIES
           8.2.1 INDEPENDENT & REFERENCE LABORATORIES ARE THE LARGEST END USERS OF ESOTERIC TESTS
                    TABLE 40 GLOBAL MARKET FOR INDEPENDENT & REFERENCE LABORATORIES, BY REGION, 2018–2026 (USD MILLION)
    8.3 HOSPITAL-BASED LABORATORIES
           8.3.1 HOSPITAL-BASED LABORATORIES ARE MORE ACCESSIBLE AND OFFER TEST RESULTS IN A SHORTER TIME PERIOD
                    TABLE 41 GLOBAL MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2018–2026 (USD MILLION)

9 ESOTERIC TESTING MARKET, BY REGION (Page No. - 110)
    9.1 INTRODUCTION
           TABLE 42 ESOTERIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 33 NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT
           TABLE 43 NORTH AMERICA: MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
           TABLE 44 NORTH AMERICA: MARKET, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 45 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
           TABLE 46 NORTH AMERICA: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 The US dominates the North American esoteric testing market
                               TABLE 47 US: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
                               TABLE 48 US: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 49 US: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 50 US: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Lack of proper reimbursements for diagnostic tests to hamper the market growth
                               TABLE 51 CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 52 CANADA: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 53 CANADA: MARKET, BY END USER, 2018–2026 (USD MILLION)
    9.3 EUROPE
           TABLE 54 EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
           TABLE 55 EUROPE: MARKET, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 56 EUROPE: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
           TABLE 57 EUROPE: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany held the largest share of the European esoteric testing market in 2020; this trend will continue in the forecast period
                               TABLE 58 GERMANY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
                               TABLE 59 GERMANY: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 60 GERMANY: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 61 GERMANY: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Rising demand for early disease diagnosis to drive market growth
                               TABLE 62 FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 63 FRANCE: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 64 FRANCE: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.3.3 ITALY
                    9.3.3.1 Rapidly growing geriatric population in Italy to favor market growth
                               TABLE 65 ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 66 ITALY: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 67 ITALY: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.3.4 UK
                    9.3.4.1 The UK is the fastest-growing market for esoteric testing in Europe due to the favorable investment scenario in the country
                               TABLE 68 UK: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 69 UK: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 70 UK: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 High burden of chronic and infectious diseases in the country to drive the adoption of esoteric tests
                               TABLE 71 SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 72 SPAIN: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 73 SPAIN: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 74 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
                    TABLE 75 ROE: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
                    TABLE 76 ROE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 77 ROE: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                    TABLE 78 ROE: MARKET, BY END USER, 2018–2026 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 34 ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT
           TABLE 79 ASIA PACIFIC: MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
           TABLE 80 ASIA PACIFIC: MARKET, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 81 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
           TABLE 82 ASIA PACIFIC: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Presence of a well-developed healthcare system to favor market growth in Japan
                               TABLE 83 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
                               TABLE 84 JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 85 JAPAN: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 86 JAPAN: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 China to register the highest growth rate in the esoteric testing market during the forecast period
                               TABLE 87 CHINA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
                               TABLE 88 CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 89 CHINA: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 90 CHINA: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Improving healthcare system in the country to support market growth
                               TABLE 91 INDIA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
                               TABLE 92 INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 93 INDIA: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 94 INDIA: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 95 ROAPAC: CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2040
                    TABLE 96 ROAPAC: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 97 ROAPAC: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                    TABLE 98 ROAPAC: MARKET, BY END USER, 2018–2026 (USD MILLION)
    9.5 LATIN AMERICA
           TABLE 99 LATIN AMERICA: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
           TABLE 100 LATIN AMERICA: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
           TABLE 101 LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
           TABLE 102 LATIN AMERICA: MARKET, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 103 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
           TABLE 104 LATIN AMERICA: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Brazil is the largest market for esoteric testing in Latin America
                               TABLE 105 BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 106 BRAZIL: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 107 BRAZIL: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.5.2 MEXICO
                    9.5.2.1 Growth in the private healthcare sector to propel market growth
                               TABLE 108 MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 109 MEXICO: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                               TABLE 110 MEXICO: MARKET, BY END USER, 2018–2026 (USD MILLION)
           9.5.3 REST OF LATIN AMERICA
                    TABLE 111 ROLATAM: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 112 ROLATAM: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                    TABLE 113 ROLATAM: MARKET, BY END USER, 2018–2026 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 IMPROVEMENTS IN THE HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET FOR ESOTERIC TESTING IN THE MEA
                    TABLE 114 AFRICA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
                    TABLE 115 MEA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 116 MEA: MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
                    TABLE 117 MEA: MARKET, BY END USER, 2018–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 155)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY ESOTERIC TESTING LABORATORIES
     10.3 REVENUE ANALYSIS
               FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN THE ESOTERIC TESTING MARKET
     10.4 MARKET SHARE ANALYSIS
               FIGURE 36 ESOTERIC TESTING MARKET SHARE ANALYSIS, 2020
               TABLE 118 ESOTERIC TESTING MARKET: DEGREE OF COMPETITION
     10.5 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS)
             10.5.1 STARS
             10.5.2 PERVASIVE PLAYERS
             10.5.3 EMERGING LEADERS
             10.5.4 PARTICIPANTS
                       FIGURE 37 ESOTERIC TESTING MARKET (GLOBAL): COMPANY EVALUATION QUADRANT, 2020
     10.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                       FIGURE 38 ESOTERIC TESTING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     10.7 COMPETITIVE BENCHMARKING
             10.7.1 COMPANY TECHNOLOGY FOOTPRINT
             10.7.2 COMPANY TESTING FOOTPRINT
             10.7.3 COMPANY REGIONAL FOOTPRINT
             10.7.4 COMPANY FOOTPRINT
     10.8 COMPETITIVE SCENARIO AND TRENDS
             10.8.1 DEALS
                       TABLE 119 DEALS, JANUARY 2018-MAY 2021
             10.8.2 SERVICE LAUNCHES & APPROVALS
                       TABLE 120 SERVICE LAUNCHES & APPROVALS, JANUARY 2018-MAY 2021
             10.8.3 OTHER DEVELOPMENTS
                       TABLE 121 OTHER DEVELOPMENTS, JANUARY 2018-MAY 2021

11 COMPANY PROFILES (Page No. - 171)
     11.1 MAJOR PLAYERS
             11.1.1 LABCORP
                       11.1.1.1 Business overview
                                   TABLE 122 LABCORP: BUSINESS OVERVIEW
                                   FIGURE 39 LABCORP: COMPANY SNAPSHOT (2020)
                       11.1.1.2 Services offered
                       11.1.1.3 Recent developments
                       11.1.1.4 MnM view
                                   11.1.1.4.1 Key strengths/right to win
                                   11.1.1.4.2 Strategic choices made
                                   11.1.1.4.3 Weaknesses and competitive threats
             11.1.2 QUEST DIAGNOSTICS
                       11.1.2.1 Business overview
                                   TABLE 123 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
                                   FIGURE 40 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2020)
                       11.1.2.2 Services offered
                       11.1.2.3 Recent developments
                       11.1.2.4 MnM view
                                   11.1.2.4.1 Key strengths/right to win
                                   11.1.2.4.2 Strategic choices made
                                   11.1.2.4.3 Weaknesses and competitive threats
             11.1.3 OPKO HEALTH, INC.
                       11.1.3.1 Business overview
                                   FIGURE 41 OPKO HEALTH: COMPANY SNAPSHOT (2020)
                       11.1.3.2 Services offered
                       11.1.3.3 Recent developments
                       11.1.3.4 MnM view
                                   11.1.3.4.1 Key strengths/right to win
                                   11.1.3.4.2 Strategic choices made
                                   11.1.3.4.3 Weaknesses and competitive threats
             11.1.4 H.U. GROUP HOLDINGS, INC.
                       11.1.4.1 Business overview
                                   TABLE 124 H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW
                                   FIGURE 42 H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
                       11.1.4.2 Services offered
                       11.1.4.3 Recent developments
             11.1.5 HEALIUS LIMITED
                       11.1.5.1 Business overview
                                   TABLE 125 HEALIUS LIMITED: BUSINESS OVERVIEW
                                   FIGURE 43 HEALIUS LIMITED: COMPANY SNAPSHOT (2020)
                       11.1.5.2 Services offered
                       11.1.5.3 Recent developments
             11.1.6 SONIC HEALTHCARE LIMITED
                       11.1.6.1 Business overview
                                   TABLE 126 SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW
                                   FIGURE 44 SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2020)
                       11.1.6.2 Services offered
                       11.1.6.3 Recent developments
             11.1.7 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)
                       11.1.7.1 Business overview
                                   FIGURE 45 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: COMPANY SNAPSHOT (2020)
                       11.1.7.2 Services offered
                       11.1.7.3 Recent developments
             11.1.8 EUROFINS SCIENTIFIC
                       11.1.8.1 Business overview
                                   TABLE 127 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
                                   FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
                       11.1.8.2 Services offered
                       11.1.8.3 Recent developments
             11.1.9 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY)
                       11.1.9.1 Business overview
                                   TABLE 128 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY): BUSINESS OVERVIEW
                       11.1.9.2 Services offered
                       11.1.9.3 Recent developments
             11.1.10 FOUNDATION MEDICINE, INC.
                        11.1.10.1 Business overview
                                   TABLE 129 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
                        11.1.10.2 Services offered
                        11.1.10.3 Recent developments
             11.1.11 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.
                        11.1.11.1 Business overview
                                   TABLE 130 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.: BUSINESS OVERVIEW
                        11.1.11.2 Services offered
                        11.1.11.3 Recent developments
             11.1.12 ARUP LABORATORIES
                        11.1.12.1 Business overview
                                   TABLE 131 ARUP LABORATORIES: BUSINESS OVERVIEW
                        11.1.12.2 Services offered
                        11.1.12.3 Recent developments
             11.1.13 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC
                        11.1.13.1 Business overview
                                   TABLE 132 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW
                        11.1.13.2 Services offered
                        11.1.13.3 Recent developments
             11.1.14 THYROCARE TECHNOLOGIES LIMITED
                        11.1.14.1 Business overview
                                   TABLE 133 THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW
                                   FIGURE 47 THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2020)
                        11.1.14.2 Services offered
             11.1.15 ACM GLOBAL LABORATORIES
                        11.1.15.1 Business overview
                                   TABLE 134 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
                        11.1.15.2 Services offered
                        11.1.15.3 Recent developments
     11.2 OTHER PLAYERS
             11.2.1 BIOAGILYTIX LABS
                       11.2.1.1 Services offered
             11.2.2 BP DIAGNOSTIC CENTRE SDN. BHD.
                       11.2.2.1 Services offered
             11.2.3 NMS LAB
                       11.2.3.1 Services offered
             11.2.4 BAYLOR ESOTERIC AND MOLECULAR LABORATORY
                       11.2.4.1 Services offered
             11.2.5 HEALTHQUEST ESOTERICS
                       11.2.5.1 Services offered
             11.2.6 CERBA XPERT
                       11.2.6.1 Services offered
             11.2.7 BUHLMANN DIAGNOSTICS CORP
                       11.2.7.1 Services offered
             11.2.8 LEO LABS, INC.
                       11.2.8.1 Services offered
             11.2.9 FLOW HEALTH
                       11.2.9.1 Services offered

12 APPENDIX (Page No. - 235)
     12.1 INSIGHTS FROM INDUSTRY EXPERTS
     12.2 DISCUSSION GUIDE
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.4 AVAILABLE CUSTOMIZATIONS
     12.5 RELATED REPORTS
     12.6 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the esoteric testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the esoteric testing market. The secondary sources used for this study include National Center for Biotechnology Information (NCBI), Royal Society of Chemistry, Springer Nature, Society for Laboratory Automation and Screening, ScienceDirect, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Nature Journals, Springer Journals, US Food and Drug Administration (US FDA), Annual Reports, SEC Filings, Investor Presentations, and Press Releases of Key Players, White Papers, Journals/Magazines, and News Articles SEC Filings, Annual Reports, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Esoteric Testing Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the esoteric testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the esoteric testing business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global esoteric testing market based on the type, technology, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall esoteric testing market
  • To analyse opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically profile the key players and comprehensively analyse their testing service portfolios, market positions, and core competencies
  • To track and analyse competitive developments such as acquisitions, service launches, expansions, agreements, partnerships, and R&D activities in the esoteric testing market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional three company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 5930
Published ON
Jun, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Esoteric Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback